Xconomy National

Archives

by in

Entry	Author	Date	Location
Dendreon Names John Johnson CEO After Volatile Year	Arlene Weintraub	02/01/12	Seattle
Dendreon Surprises With $82M in Fourth Quarter Sales, Stock Booms	Luke Timmerman	01/05/12	Seattle
Dendreon Pulls In $125M By Selling Royalty Slice of Merck’s Hepatitis C Drug	Luke Timmerman	12/06/11	Seattle
Medivation, Astellas Prostate Cancer Drug Helps Men Live Longer; Shares Skyrocket	Luke Timmerman	11/03/11	San Francisco
Dendreon Shares Tank Again, Elias Joins Gates Foundation, Seattle Children’s Gets $50M, & More Seattle-Area Life Sciences News	Luke Timmerman	11/03/11	Seattle
Dendreon Edges Past Street Expectations With Third Quarter Provenge Sales, Shares Still Fall	Luke Timmerman	11/02/11	Seattle
Chris Henney, the Immunex and Dendreon Mover/Shaker, Makes Biotech Hall of Fame	Luke Timmerman	10/17/11	Seattle
Dendreon Concentrates Job Cuts in Manufacturing, but Seattle Feels the Axe Too	Luke Timmerman	09/08/11	Seattle
Dendreon Whacks 500 Jobs, 25% of Workforce, After Missing Sales Goal	Luke Timmerman	09/08/11	Seattle
Theraclone Sniffs Around for $10M, Dendreon Gets Third Factory OK, Zymeworks’ Big Merck Deal, & More Seattle-Area Life Sciences News	Luke Timmerman	09/08/11	Seattle
(Mis)Understanding Drug Discovery: It’s Much Harder Than Rocket Science	Stewart Lyman	09/07/11	Seattle
Dendreon Wins FDA OK for Atlanta Provenge Factory, Completing National Network	Luke Timmerman	08/26/11	Seattle
Dendreon Adds Ex-ImClone CEO to Board	Luke Timmerman	08/22/11	Seattle
Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus	Luke Timmerman	08/08/11	National
An Open Letter to Dendreon’s Chairman	Brad Loncar	08/05/11	Seattle
Dendreon Takes Huge Hit, Stock Tanks 60% on Sales Shortfall	Luke Timmerman	08/03/11	Seattle
Dendreon Misses Street Expectations, Plans Layoffs, Backs Away from Bullish Forecast	Luke Timmerman	08/03/11	Seattle
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent	Luke Timmerman	07/18/11	National
Dendreon, After Yearlong Inquiry, Sways Medicare to Pay for $93,000 Prostate Cancer Drug	Luke Timmerman	06/30/11	Seattle
Gates Bets on Computer Drug Discovery, Tachi Yamada Joins Frazier, Dendreon’s LA OK, & More in Seattle-Area Life Sciences News	Luke Timmerman	06/30/11	Seattle
Dendreon Gets FDA Nod for New LA Cancer Drug Factory	Luke Timmerman	06/29/11	Seattle
Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients	Luke Timmerman	06/06/11	San Francisco
Accelerator’s New Startup, Oncofactor, Seeks to Spark Immune System Fight Against Cancer	Luke Timmerman	05/24/11	Seattle
The Resurgence of Gene and Cell Therapy	Barrie Carter	05/16/11	Seattle
Kleiner Perkins’ Bet on a Concrete Stomach, The Gates Foundation’s Out-of-the-Box Ideas, & More Seattle-Area Life Sciences News	Luke Timmerman	05/05/11	Seattle
Dendreon Gets $28M Revenue in Q1	Luke Timmerman	05/02/11	Seattle
Dendreon Faces Internet-Fueled Shareholder Uprising, Led by a Little Guy in Kansas	Luke Timmerman	04/01/11	Seattle
Dendreon Wins Full Reimbursement From Medicare for $93K Prostate Cancer Drug	Luke Timmerman	03/30/11	Seattle
Think Obamacare Will Suffocate New Drug Development With Price Controls? Think Again	Luke Timmerman	03/21/11	National
Dendreon’s Warhorse, Chief Scientific Officer Dave Urdal, To Retire at Year-End	Luke Timmerman	03/11/11	Seattle
Page 1 of 5	next page »